Notably, the percentage of women taking drugs, such as tamoxifen, which can affect IGF-1 levels, was not significantly different between the two groups (46.6 and 46.2 in MetS and NoMetS, respectively, p = 0.995). Here, IGF1 is linked to metabolic syndrome.